Libia Chandler
Surgical · Springfield, MONPI 1841398153
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $205 and has fallen 82.6% since, to $36 in 2023.
Across 25 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$49
- Boehringer Ingelheim$44
- Novo Nordisk$40
- Astellas Pharma US Inc$38
- AbbVie$37
- Takeda Pharmaceuticals U.S.A., Inc.$36
- plus $171 from 10 others
What the payments were for
- Food & beverage$416100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 3 | $49 |
| Boehringer Ingelheim | 3 | $44 |
| Novo Nordisk | 2 | $40 |
| Astellas Pharma US Inc | 2 | $38 |
| AbbVie | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Medtronic | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Bayer | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Amgen | 1 | $12 |
How this compares
$416 in reported general payments places this provider in the 55th percentile of 118 surgical providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 14 | $247 |
| Cephalexin | 37 | $228 |
| Doxycycline Hyclate | 20 | $160 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $136 |
| Prednisone | 22 | $30 |
Paid to pharmacies, not to this prescriber.
Other surgical in Springfield
- Chad NallSpringfield$6K
- Frances AbbiattiSpringfield$3K
- Chad OliverSpringfield$3K
- Darin FincherSpringfield$1K
- Heather TackettSpringfield$983
- Mark BrownSpringfield$658
- Blake MartinSpringfield$569
- Joshua BarbieriSpringfield$398
- Ciara GlennSaint Louis$9K
- Thomas PrangeSaint Louis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.